HANSOH PHARMACEUTICAL GROUP COMPANY LIMITED

Hansoh Pharmaceutical Group Company Limited

3692

KYG549581067

Pharmaceuticals

Market Closed - Hong Kong S.E. Other stock markets 16:08:09 19/06/2025 HKT			5-day change	1st Jan Change
27.75 ^HKD	-1.42%		-7.19%	+60.59%

06-05	Hansoh Pharmaceutical Group Company Limited Announces Approval of Aumolertinib Mesilate Tablets by the Medicines and Healthcare Products Regulatory Agency for Marketing	CI
06-04	Hansoh Pharmaceutical Says Aumolertinib Mesilate Tablets Approved By MHRA For Marketing	RE

Hansoh Pharmaceutical: The silent revolution in Chinese biopharma

Published on 16/05/2025 at 19:44

By Tommy Douziech

Hansoh Pharmaceutical: The silent revolution in Chinese biopharma

Founded in 2015 in Shanghai by Hui Juan Zhong, Hansoh Pharmaceutical Group Co., Ltd. has risen in less than a decade to become one of the jewels of Chinese biopharmaceuticals. Formerly focused on generic drugs, the company is now undergoing a radical and successful transformation to become a leader in therapeutic innovation, particularly in oncology, central nervous system disorders, obesity, diabetes, and infections.

This article is for Premium subscribers only

SUBSCRIBE to Premium to unlock this high value-added content!

Already a customer? Log In

Tommy Douziech

Senior Analyst

The content herein constitutes a general investment recommendation, prepared in accordance with provisions aimed at preventing market abuse by Surperformance, the publisher of MarketScreener Hong Kong. More specifically, this recommendation is based on factual elements and expresses a sincere, complete, and balanced opinion. It relies on internal or external data, considered reliable as of the date of their release. Nevertheless, this information, and the resulting recommendation, may contain inaccuracies, errors, or omissions, for which Surperformance cannot be held responsible. This recommendation, which in no way constitutes investment advice, may not be suitable for all investor profiles. The reader acknowledges and accepts that any investment in a financial instrument involves risks, for which they assume full responsibility, without recourse against Surperformance. Surperformance commits to disclosing any conflict of interest that may affect the objectivity of its recommendations.
Surperformance is Buy on HANSOH PHARMACEUTICAL GROUP COMPANY LIMITED since 13/05/2025 .

Latest news about Hansoh Pharmaceutical Group Company Limited

Hansoh Pharmaceutical Group Company Limited Announces Approval of Aumolertinib Mesilate Tablets by the Medicines and Healthcare Products Regulatory Agency for Marketing	06-05	CI
Hansoh Pharmaceutical Says Aumolertinib Mesilate Tablets Approved By MHRA For Marketing	06-04	RE
Hansoh Pharma's Lung Cancer Drug Aumseqa Wins UK Marketing Approval	06-04	MT
Nomura Adjusts Hansoh Pharmaceutical Group's Price Target to HK$25.64 From HK$19.86, Keeps at Neutral	06-03	MT
Hansoh Pharma Licenses GLP-1 Drug to Nasdaq-listed Regeneron in $2 Billion Deal	06-03	MT
Regeneron's weight-loss drug helps patients on Wegovy preserve muscle	06-03	RE
Hansoh Pharmaceutical Says Units Entered Into A License Agreement With Regeneron Pharmaceuticals	06-02	RE
Regeneron Signs Licensing Agreement for Chinese Weight Loss Drug	06-02	DJ
Hansoh Pharmaceutical Group Company Limited Announces the Third Biologics License Application of Xin Yue (Inebilizumab Injection) Has Been Accepted by the National Medical Products Administration	05-31	CI
Hansoh Pharmaceutical Says Third Biologics License Application Of Xinyue (Inebilizumab Injection) Accepted By NMPA	05-31	RE
Chinese Regulator Accepts Hansoh Pharmaceutical's License Application for Generalized Myasthenia Gravis Drug	05-30	MT
Hansoh Pharmaceutical Group Company Limited Obtains Clinical Trial Approval Issued by the National Medical Products Administration	05-30	CI
Hansoh Pharmaceutical Group Company Limited Obtains Clinical Trial Approval Issued by the National Medical Products Administration	05-30	CI
Hansoh Pharmaceutical Group Company Limited Obtains Clinical Trial Approval Issued by the National Medical Products Administration	05-30	CI
Hansoh Pharmaceutical Says Clinical Trial Approval For HS-10542 Capsules Issued By NMPA	05-30	RE
Hansoh Pharmaceutical Gets China Nod for Clinical Trial of Three Drugs	05-29	MT
Hansoh Pharmaceutical Says Clinical Trial Approval For HS-20118 Tablets Issued By NMPA	05-29	RE
Hansoh Pharmaceutical Says Clinical Trial Approval For HS-10510 Tablets Issued By NMPA	05-29	RE
Weight-loss drug developers line up to tap lucrative market as competition heats up	05-17	RE
New purchases in the Asia Investor portfolio	05-14
Hansoh Pharmaceutical Gets China Registration Nod for New Indication of Lung Cancer Drug	05-12	MT
Asia Pharma Stocks Fall After Trump's Plan to Cut Drug Costs	05-12	DJ
Hansoh Pharmaceutical Says Drug Registration Approval Of Fourth Indication Of Aumolertinib Mesilate Tablets Granted By NMPA	05-09	RE
Hansoh Pharmaceutical Group Company Limited Announces Drug Registration Approval of the Fourth Indication of Ameile (Aumolertinib Mesilate Tablets) Granted by the National Medical Products Administration	05-09	CI
Hansoh Pharma Gets Breakthrough Therapy Deisgnation for Ovarian, Fallopian Tube Cancer Drug	05-02	MT

Chart Hansoh Pharmaceutical Group Company Limited

Duration

Period

Chart Hansoh Pharmaceutical Group Company Limited

3692: Dynamic Chart

Company Profile

Hansoh Pharmaceutical Group Company Ltd is an investment holding company primarily engaged in the research and development, production and sale of a series of pharmaceutical products. The Companyâs innovative drug products include Ameile, Hansoh Xinfu, Mailingda, Fulaimei, Hengmu, XINYUE, Saint Luolai and other products. The Companyâs drug products are mainly used in oncology, anti-infective diseases, central nervous system (CNS) diseases, metabolic diseases and other therapeutic areas. The Company mainly conducts its business in the domestic market.

Employees

8,989

Sector

Pharmaceuticals

Calendar

06-20 - Annual General Meeting

More about the company